Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
DrugBank Accession Number
DB10998
Background

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
  • influenza A virus A/Brisbane/10/2010 (H1N1) antigen

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Influenza A virus A/Brisbane/10/2010 (H1N1) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)hemagglutininKFL1W6W9JBNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FlucelvaxInfluenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Wisconsin/1/2010) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularNovartis Vaccines and Diagnostics GmbH2012-11-302012-11-19US flag
FlucelvaxInfluenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularNovartis Vaccines And Diagnostics, Inc.2014-07-012015-06-30US flag
FlucelvaxInfluenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/South Australia/55/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularNovartis Vaccines And Diagnostics, Inc.2014-07-012016-06-30US flag
FlucelvaxInfluenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularNovartis Vaccines and Diagnostics GmbH2013-08-302014-06-30US flag
Flucelvax QuadrivalentInfluenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Hong Kong/259/2010 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus, Inc.2016-07-012017-06-30US flag
Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 KitInfluenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Isopropyl alcohol (70 mL/100mL)KitTopicalAsclemed Usa, Inc.2013-07-012015-06-30US flag
Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/South Australia/55/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Isopropyl alcohol (70 mL/100mL)KitTopicalAsclemed Usa, Inc.2014-07-012016-06-29US flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
DES33X6VK7
CAS number
Not Available

References

General References
Not Available
RxNav
1657127

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingBasic ScienceFlu caused by Influenza1
4Active Not RecruitingPreventionFlu caused by Influenza1
4CompletedBasic ScienceFlu caused by Influenza1
4CompletedOtherAsthma1
4CompletedPreventionImmune Responses / Influenza, Human2
4Not Yet RecruitingBasic ScienceCoronavirus Disease 2019 (COVID‑19) / Malignant Lymphomas1
4RecruitingBasic ScienceFlu caused by Influenza1
3Active Not RecruitingPreventionInfluenza, Human1
3CompletedPreventionFlu caused by Influenza / Humans / Virus Diseases1
3CompletedPreventionInfluenza, Human1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
KitTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:05 / Updated at June 12, 2020 16:53